 |
Joele Frank is handling Forma Therapeutics as the Watertown, MA-based biopharmaceutical company focused on sickle cell disease and other blood disorders is acquired by Novo Nordisk for $1.1B cash.
The Danish company has developed Etavopivat, which is currently being evaluated in global trials to treat sickle cell disease.
“Novo Nordisk has worked for more than 40 years to develop and deliver transformative medicines to patients around the world with rare and devastating diseases,” said Ludovic Helfgott, EVP and head of rare disease unit.
The addition of Forma’s ‘differentiated approach’ to address unmet needs for patients is a step forward in enhancing our sickle cell disease pipeline.” added Helftogg.
Joele Frank, Wilkinson Brimmer Katcher’s Jamie Moser and Greg Klassen represent Forma Therapeutics.
Jenn Kettnich, who has more than 15 years of financial communications experience, has joined Liftoff Mobile as VP-investor relations following completion of its recent IPO.
Joele Frank handles Crinetics Pharmaceuticals as the specialist for treatments for endocrine diseases agrees to get acquired by Vertex Pharmaceuticals in a deal pegged at $8.8B.
Teneo represents Honeywell spin-off Solstice Advanced Materials as it buys Collected Strategies client Element Solutions in a deal pegged at $14.5B.
Dallas-based Throughline Global Advisors advised Principal Mineral as it acquired Isola Group, maker of copper-clad laminates used in printed circuit boards.
oele Frank works for satellite operator Iridium Communications as it gets acquired by space company Rocket Lab in a deal worth $8B.
